Skip to main content

View full-text article in PMC

. 2012 Jan 5;8(1):e1002339. doi: 10.1371/journal.pcbi.1002339

Table 1. Contribution of telaprevir and PR treatment to the antiviral blockage and infected-cell clearance rates in treatment-naïve patient population.

Variant Name	Level of resistance	Antiviral blockage log₁₀(1- ε)						infected-cell clearance δ (d⁻¹)
		PegIFN/RBV			telaprevir
		Median	5^th%	95^th%	Median	5^th%	95^th%	Median	5^th%	95^th%
WT	None	−1.09	−1.28	−0.76	−2.27	−2.68	−1.69	0.62	0.36	1.42
R155K	Lower	−1.09	−1.28	−0.76	−2.51	−3.40	−1.28	0.65	0.36	1.54
V36A	Lower	−1.09	−1.28	−0.76	−2.39	−3.25	−1.19	0.65	0.36	1.49
A156T	Higher	−1.09	−1.28	−0.76	−0.01	−0.02	0.00	0.29	0.24	0.36
V36M/R155K	Higher	−1.09	−1.28	−0.76	0.00	−0.01	0.00	0.29	0.24	0.36